Compare Expensify Inc (EXFY) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Globus Medical Inc. Class A Common Stock — how do they compare? Expensify Inc trades at $2.44 (market cap $222.95M), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 46× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| EXFY | GMED | |
|---|---|---|
Market Cap | $222.95M | $10.25B |
Volume | 293,722 | 1,108,124 |
Sector | Technology | Health |
52-Week High | $2.72 | $96.82 |
52-Week Low | $0.75 | $58.33 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | $162.57M | $9.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.45, showing modest daily gains of 0.41%. The stock exhibits a bullish technical signal with strong moving average support. Fundamentally, the company maintains solid revenue around $142M but faces profitability challenges with negative net margins. Recent quarterly earnings show mixed results with two beats and one miss. Analyst sentiment leans positive with a 50% buy rating and $13.75 consensus price target, representing significant upside potential from current levels.
EXFY presents a high-risk, high-reward opportunity with substantial analyst upside but persistent profitability concerns. The company's expansion into European markets and AI integrations provide growth catalysts, though negative earnings and cash flow volatility remain key risks. Investors should weigh the significant price target premium against the company's ongoing transition to profitability.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
